Ideaforge Technology Limited made a blockbuster debut on the stock market on Friday. The stock listed at ₹1,300 on the NSE, over 90% from its issue price of ₹672. The company, which was featured in the popular Bollywood movie ‘3 Idiots‘, launched its IPO last month and received a stellar response.
The Investment: If you had invested ₹14,784 in Ideaforge’s IPO, you would have been able to purchase 22 shares at the issue price of ₹672 per share. The Ideaforge IPO’s lot size was 22 shares, and if an investor wanted to subscribe to the IPO they would have had to buy a minimum of 1 lot.
So, if you did that, and were lucky enough to get the allotment, today, those shares would be worth ₹28,600, given the current market price of ₹1,300 per share. That’s a significant return of 93% on your investment.
See Also: IPO-Ready IdeaForge Aims To Make A Splash In The US With Its Drone Tech
Background: Ideaforge Technology, founded by IIT Bombay alumni, designs and manufactures drones for mapping, security, and surveillance applications. The company’s IPO, which aimed to raise ₹576 crore, was a significant event as it marked Ideaforge as the first drone company to issue a main board IPO.
The IPO experienced an extraordinary oversubscription of 106.06 times. The oversubscription ratios for different categories of investors in the IdeaForge Technology IPO were as follows: Institutional investors subscribed 125.81 times, non-institutional investors subscribed 80.58 times, retail investors subscribed 85.20 times, and employee reserved shares were oversubscribed by 96.65 times.
Get Ring The Bell, Benzinga India’s weekly briefing. Designed specifically for investors like you.
Read Next: This Tata Stock Made Rekha Jhunjhunwala ₹480 Cr Richer Today
Price Action: At the time of writing, Ideaforge’s share traded 0.79% lower from the listing price at ₹1,289.75.
Disclaimer: Benzinga India doesn’t give financial advice. The above article is for educational purposes alone.
Editor’s Note: Artificial intelligence was used as a secondary aid in the writing of this story.
© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.